Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis
Posted inDiabetes & Endocrinology news Rheumatology

Short-Course Romosozumab Followed by Denosumab Is Non-Inferior to Standard 12-Month Regimen for Postmenopausal Osteoporosis

The LIDA trial demonstrates that a 3-month abbreviated course of romosozumab followed by denosumab is non-inferior to the standard 12-month regimen in increasing total hip bone mineral density, potentially reducing treatment costs and injection burden for high-risk postmenopausal women.
ESTIVAL Trial: Auricular Vagus Nerve Stimulation for Erosive Hand Osteoarthritis Falls Short of Primary Endpoint but Shows Signals in Inflammatory Subgroups
Posted innews Rheumatology

ESTIVAL Trial: Auricular Vagus Nerve Stimulation for Erosive Hand Osteoarthritis Falls Short of Primary Endpoint but Shows Signals in Inflammatory Subgroups

The ESTIVAL trial investigated transcutaneous auricular vagus nerve stimulation (taVNS) for erosive hand osteoarthritis. While the primary pain reduction endpoint was not met, the therapy proved safe and showed potential efficacy in patients with significant synovial inflammation, suggesting a need for phenotype-specific research.
Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?
Posted inDermatology news Rheumatology

Aggressive Initial Management in Early Psoriatic Arthritis: Does Adding Golimumab to Methotrexate and Steroids Offer Superior Outcomes?

The GOLMePsA trial found no significant difference in disease activity at 24 weeks when adding golimumab to methotrexate and steroids for early PsA. However, the triple therapy significantly reduced the need for rescue corticosteroids, highlighting potential steroid-sparing benefits in early intervention.
Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis
Posted innews Orthopedics Rheumatology

Cycling into Relief: The CLEAT Trial Validates Community-Based Exercise for Hip Osteoarthritis

The CLEAT trial demonstrates that an 8-week cycling and education program (CHAIN) significantly improves function in hip osteoarthritis compared to usual physiotherapy. Despite falling just short of the clinical importance threshold, its high cost-effectiveness positions it as a viable community-based alternative for the NHS.
The Rising Burden of Sarcoidosis in England: New Evidence of Increasing Incidence and Significant Mortality Gaps
Posted innews Respiratory Rheumatology

The Rising Burden of Sarcoidosis in England: New Evidence of Increasing Incidence and Significant Mortality Gaps

A landmark study of over 18,000 patients reveals that sarcoidosis incidence and prevalence in England are rising, particularly among older adults. With a 36% higher mortality risk compared to the general population, these findings demand a shift in how the healthcare system prioritizes this complex multisystem disease.